Direct-to-consumer genomic testing Contents



1 Introduction


The human genome

Commercial genomic testing


Our inquiry

2 The benefits and risks of direct-to-consumer genomic testing

Potential benefits and risks

Health benefits and risks

Informing parental decisions

Impact on the NHS

Research benefits

Economic opportunity

Privacy and consent

Evidence of benefits and risks

The case for updated regulation

3 Supporting a responsible direct-to-consumer genomic testing industry

Continued support for the UK genomics sector

Ensuring a responsible, trusted genomic testing industry

External validation

Technical standards

Analytic and clinical performance

Support for the NHS

Data protection

Permitted uses of genomic testing

Testing children

Prenatal testing

Regulatory scope

Regulating an international market

Secondary analysis

Conclusions and recommendations

Formal minutes


Published written evidence

List of Reports from the Committee during the current Parliament

Published: 22 June 2021 Site information    Accessibility statement